Co-Diagnostics

The pivot from a withdrawn OTC COVID-only submission to the ABCR multiplex respiratory test works because multiplex flu A/B, COVID-19 and RSV testing is a more clinically useful point-of-care use case for Co-Dx PCR. If this holds, CODX can restart demand from a very low base; if it fails, the company remains a tiny legacy reagent seller with an expensive development program.

Co-Primers’ claimed specificity, multiplexing suitability and royalty-free owned platform let CODX compete as a low-cost molecular diagnostics provider while preserving reagent economics; if customers see no measurable accuracy or cost edge, pricing power disappears. This is the mechanism that could turn commercialization into gross profit rather than revenue bought with weak pricing.

Owning the assay-design platform gives CODX an option on emerging-pathogen demand because it can rapidly design and seek approval for new molecular tests, but that option is episodic rather than a stable base business. This defines CODX as a high-upside but irregular demand story rather than a predictable diagnostics compounder.

The platform option only has equity value if management materially slows cash burn or funds ABCR validation without punitive dilution, because the current development spend overwhelms the balance sheet before commercialization. Even a viable product can fail shareholders if the company must finance it from a position of distress.

A high-margin consumables model can emerge only if the Co-Dx PCR instrument, test cup and app create an installed base; otherwise CODX’s regulatory and R&D infrastructure remains a fixed-cost trap. This separates a scalable diagnostics platform from a cash-consuming product-development company.